3 Key Takeaways
Plain English Summary- 01Core Finding
A substantial HbA1c reduction was observed when AID was added to prestudy use of a glucagon-like peptide 1 receptor agonist or sodium-glucose cotransporter 2 inhibitor drug, which was continued during the trial.
- 02Study Evidence
Tested in a Phase III multicenter trial · Phase III clinical trial at the Phase III stage.
- 03Practical Meaning
Large Phase III clinical evidence — long-term durability and rare subgroup effects remain under study.
What This Means for You
In this single-arm, 13-week trial in adults with insulin-treated type 2 diabetes, AID with the twiist system was safe and associated with substantially improved glycemia.
Published in Diabetes care, these peer-reviewed endocrinology findings provide quantitative clinical evidence to inform risk stratification, therapeutic decision-making, and follow-up validation.
The Discovery
To evaluate the efficacy (real-world effectiveness in the trial), safety, and user satisfaction of the twiist automated insulin delivery (AID) system in adults with type 2 diabetes. Mean HbA1c decreased by 0.7% (95% CI -0.9 to -0.6) from a clinically meaningful level ± 1.5% at baseline to 7.4% ± 0.9% after using twiist for 13 weeks (P < 0.001 for both noninferiority and superiority). The treatment effect was greatest in participants with baseline HbA1c ≥a clinically meaningful level. A substantial HbA1c reduction was observed when AID was added to prestudy use of a glucagon-like peptide 1 receptor agonist or sodium-glucose cotransporter 2 inhibitor drug, which was continued during the trial. Mean CGM-measured time-in-range 70-180 mg/dL increased from 57% ± 26% to 73% ± 17% (mean change 16% [95% CI 14-18]; P < 0.001). All other multiplicity-controlled CGM outcomes reflective of hyperglycemia showed significant improvement from baseline. The frequency of CGM-measured hypoglycemia was low at baseline and remained low during follow-up. Diabetic ketoacidosis occurred in one participant; no severe hypoglycemia events occurred. Using twiist, participant satisfaction was higher than with their prestudy insulin delivery method (P < 0.001) and sleep quality improved (P < 0.001).
How It Works, Simply
This endocrinology research focuses on insulin · Receptor targeting. Researchers evaluated it using a phase III multicenter trial · Phase III clinical trial at the Phase III stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
A substantial HbA1c reduction was observed when AID was added to prestudy use of a glucagon-like peptide 1 receptor agonist or sodium-glucose cotransporter 2 inhibitor drug, which was continued during the trial.
- 02Study Evidence
Tested in a Phase III multicenter trial · Phase III clinical trial at the Phase III stage.
- 03Practical Meaning
Large Phase III clinical evidence — long-term durability and rare subgroup effects remain under study.
Key Numbers
Biological Mechanism & Study Design
Study Design & Cohort
Phase III clinical trial
Phase III multicenter trial · Phase III clinical trial · Phase III
Biological Pathway & Modality
Insulin · Receptor targeting
Intervention: A Multicenter 13-Week Evaluation of the twiist Automated Insulin Delivery in
Experimental Findings & Endpoints
To evaluate the efficacy, safety, and user satisfaction of the twiist automated insulin delivery (AID) system in adults with type 2 diabetes.
Mean HbA1c decreased by 0.7% (95% CI -0.9 to -0.6) from a clinically meaningful level ± 1.5% at baseline to 7.4% ± 0.9% after using twiist for 13 weeks (P < 0.001 for both noninferiority and superiority). The treatment effect was greatest in participants with baseline HbA1c ≥a clinically meaningful level.
A substantial HbA1c reduction was observed when AID was added to prestudy use of a glucagon-like peptide 1 receptor agonist or sodium-glucose cotransporter 2 inhibitor drug, which was continued during the trial. Mean CGM-measured time-in-range 70-180 mg/dL increased from 57% ± 26% to 73% ± 17% (mean change 16% [95% CI 14-18]; P < 0.001).
All other multiplicity-controlled CGM outcomes reflective of hyperglycemia showed significant improvement from baseline. The frequency of CGM-measured hypoglycemia was low at baseline and remained low during follow-up.
Diabetic ketoacidosis occurred in one participant; no severe hypoglycemia events occurred. Using twiist, participant satisfaction was higher than with their prestudy insulin delivery method (P < 0.001) and sleep quality improved (P < 0.001).
Clinical Translation & Practice Context
In this single-arm, 13-week trial in adults with insulin-treated type 2 diabetes, AID with the twiist system was safe and associated with substantially improved glycemia.
Published in Diabetes care, these peer-reviewed endocrinology findings provide quantitative clinical evidence to inform risk stratification, therapeutic decision-making, and follow-up validation.
The Bottom Line · Clinical Pearl
“In this single-arm, 13-week trial in adults with insulin-treated type 2 diabetes, AID with the twiist system was safe and associated with substantially improved glycemia.”
Published in Diabetes Care · Current Stage: Phase III